ITA2565
ITA2565
- Catalog: ITA2565
- Gene/Protein: HCAR2
- Product Description: Immunotag™ GPR109A/B Antibody
385.0000
Price in reward points: 385
| Antibody Specification | |
| Datasheet |
|
| Target Protein | GPR109A/B |
| Clonality | Polyclonal |
| Storage/Stability | -20°C/1 year |
| Application | WB,ELISA |
| Recommended Dilution | WB 1:1000-3000 |
| Concentration | 1 mg/ml |
| Reactive Species | Human |
| Host Species | Rabbit |
| Immunogen | A synthesized peptide derived from human GPR109A/B |
| Specificity | GPR109A/B Antibody detects endogenous levels of total GPR109A/B |
| Purification | The antiserum was purified by peptide affinity chromatography. |
| Form | Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt |
| Gene Name | HCAR2 |
| Accession No. | Q8TDS4/P49019 |
| Alternate Names | G protein coupled receptor 109A; G protein coupled receptor HM74a; G protein coupled receptor Hm74b; G-protein coupled receptor 109A; G-protein coupled receptor HM74A; G109A_HUMAN; GPR 109A; Gpr109a; GPR109A protein; HCA2; HCAR2; HM 74; HM 74a; HM 74b; Hm74; HM74a; HM74b; hydroxycarboxylic acid receptor 2; Interferon gamma inducible gene Puma g; Niacin receptor 1; NIACR1; Nicotinic acid receptor 1; Nicotinic acid receptor; Protein upregulated in macrophages by IFNG, mouse, homolog of; Puma g; Pumag; rHM74b; G protein coupled receptor 109B; G protein coupled receptor HM74; G protein coupled receptor HM74B; G-protein coupled receptor 109B; G-protein coupled receptor HM74; G-protein coupled receptor HM74B; GPR109B; HCA3; HCAR3; HCAR3_HUMAN; HM74; HM74B; Hydroxycarboxylic acid receptor 3; Niacin receptor 2; NIACR2; Nicotinic acid receptor 2; Puma g; PUMAG; |
| Description | Acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide. |
| Cell Pathway/ Category | Primary Polyclonal Antibody |
| Protein MW | 43 kDa |
| Usage | For Research Use Only! Not for diagnostic or therapeutic procedures. |
| Material Safety Data Sheet | |
| English_US |
|
| Danish |
|
| Dutch |
|
| English_UK |
|
| French |
|
| German |
|
| Spanish |
|
| Norwegian |
|
| Portuguese |
|
| Finnish |
|
| Swedish |
|
| Polish |
|